FDA approves Adbry autoinjector for atopic dermatitis

Key takeaways:

• Adbry is approved for moderate to severe atopic dermatitis.
• The autoinjector delivers a single 300 mg/mL dose.

The FDA has approved a single-dose autoinjector for Adbry, LEO Pharma announced in a press release.

Adbry (tralokinumab-ldrm), a high-affinity fully human monoclonal antibody that binds and inhibits interleukin-13, is approved for the treatment of moderate to severe atopic dermatitis in patients aged older than 12 years.

The new autoinjector device, which delivers a single 300 mg/2 mL dose of Adbry, will be available for adult patients.

“We are constantly looking for new ways to advance the standard of care and improve the patient experience for our treatment options,” Brian Hilberdink, executive vice president of LEO Pharma’s North American region, said in the release. “Through this latest approval, a new mode of administration has been made available to provide a more convenient option to support self-administration.”

Adbry is also available in a 150 mg/1 mL pre-filled syringe in the U.S.

“We understand that no patient is the same, and through this extended approval we have taken a positive step forward to equip those living with AD with more choices,” Shannon Schneider, LEO Pharma senior medical affairs director, said in the release. “Alongside the previously approved pre-filled syringe, the autoinjector will give adult patients in the U.S. more options than ever before in how they administer their treatment.”